[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100370705":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":45,"centralContacts":49,"locations":54,"responsibleParty":71,"collaborators":10,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":10,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":88,"studyType":89,"phases":10,"briefSummary":90,"conditions":91,"keywords":10,"overallStatus":56,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14,18,22,25,29],{"label":9,"type":10,"description":11,"interventionNames":12},"NMOSD",null,"Patients with neuromyelitis optica spectrum disorders",[13],"Drug: Intravenous steroid",{"label":15,"type":10,"description":16,"interventionNames":17},"Multiple sclerosis(MS)","Patients with multiple sclerosis",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"MOGAD","Patients with myelin oligodendrocyte glycoprotein antibody-associated disease",[13],{"label":23,"type":10,"description":24,"interventionNames":10},"Healthy controls (HC)","Healthy people without any neuroinflammation disease",{"label":26,"type":10,"description":27,"interventionNames":28},"PACNS","primary angiitis of the central nervous system",[13],{"label":30,"type":10,"description":31,"interventionNames":32},"AE","autoimmune encephalitis",[13],[34],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DRUG","Intravenous steroid","This study does not limit treatment methods. During the acute stage, patients commonly receive high-dose intravenous methylprednisolone (1g daily for 3-5 days). For severe or refractory cases, plasma exchange (PLEX) or intravenous immunoglobulin (IVIG) may be added. For PACNS, cyclophosphamide is added to steroids as standard induction. During remission, immunomodulatory or immunosuppressive therapies vary by disease: for MS, DMTs such as ocrelizumab or natalizumab; for NMOSD, rituximab (500mg on day 1 and 15, then every 6 months), eculizumab, or satralizumab; for MOGAD, azathioprine, mycophenolate mofetil, or rituximab but only for relapsing patients; for PACNS, azathioprine or mycophenolate mofetil for 12-18 months after cyclophosphamide; for AE, rituximab or cyclophosphamide for refractory cases, with maintenance only for relapsing forms.",[30,19,15,9,26],[40,41,42,43,44],"Azathioprine","Mycophenolate Mofetil","Rituximab","Natalizumab","Cyclophosphamide",[46],{"name":47,"affiliation":5,"role":48},"Yaou Liu, PhD","PRINCIPAL_INVESTIGATOR",[50],{"name":47,"role":51,"phone":52,"phoneExt":10,"email":53},"CONTACT","+86 1059975396","yaouliu80@163.com",[55],{"facility":5,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"RECRUITING","Beijing","Beijing Municipality","100053","China","CN",{"type":63,"coordinates":64},"Point",[65,66],116.39723,39.9075,{"lat":66,"lon":65},[69],{"name":70,"role":51,"phone":52,"phoneExt":10,"email":53},"Yaou Liu, PHD",{"type":48,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Yaou Liu","Professor","100370705","clinical-and-imaging-cohort-of-neuroinflammation-diseases-in-china-clue-100370705",false,"NCT04106830","Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)","Prospective Cohort Study of cLinical and Imaging Patterns of neUroinflammation disEases (CLUE)","Inclusion Criteria:\n\n* 16-75\n* Diagnosis of neuroinflammatory and demyelination disease\n* Availability of demographic and clinical data at the time disease onset\n* Informed written consent obtained from the patient, and\u002For patient's parent(s), and\u002For legal representative. Assent, if old enough to grant, will be obtained from all patients under the age of 16 years.\n\nExclusion Criteria:\n\n* Patients for whom MRI is contra-indicated\n* Patients included in an ongoing clinical trial where the product is blinded",true,"ALL","16 Years","75 Years",{"count":86,"type":87},1000,"ESTIMATED","12 Months","OBSERVATIONAL","CLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases. Participants will receive magnetic resonance (MR) techniques including DIR, DKI, QSM, Rs-fMRI, conventional sequences (T1WI\u002FT2WI\u002FFLAIR), and the MR metabolic SPICE sequence, and will be followed up for one year using 3T MRI. In addition, participants will receive a one-time baseline examination including T1WI, T2WI, FLAIR, and SWI sequences on 7T MRI, as well as PET-MRI.",[92,93,94,19],"NMO Spectrum Disorder","MRI","Multiple Sclerosis","2026-06-12",{"date":97,"type":98},"2026-06-15","ACTUAL",{"date":100,"type":98},"2019-01-01",{"date":102,"type":87},"2028-12-31",{"name":5,"class":6},1]